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Hemopoiesisin both mouse and man has been the focusof intense investigation
in recent years . Dramatic progress has been achieved in resolving the various
growth factors involved in many of the major hemopoietic lineages . ThecDNAs
encoding growth and differentiation factors active on multipotential cells (1-3)
and on the granulocytic (4), eosinophilic (5), monocytic (6), and erythroid (7)
lineages have now been cloned and expressed . In contrast, very little is known
about the regulatory factors involved in the commitment and differentiation of
precursor cells along the pathway of lymphogenesis . The pluripotent lymphoid
stem cell has not been identified, nor have the factors or conditions required for
commitment and expansion of the B cell lineage . The later stages of B cell
growth and differentiation after the appearance of surface Ig and the emergence
of the B cell from the bone marrow have been the most well studied and have
revealed a number of factors that are active on mature peripheral B cells. These
include IL-1 (8), IL-2 (9), IL-4 (10, 11), IL-5 (12), IFN-y (13), IFN-,B2 (14),
neuroleukin (15), and transforming growth factor ,8 (16) .
Most of the available evidence on B cell generation has been limited to those
B cells that are thought to be the immediate precursors of mature functional
peripheral B cells . These pre-B cells have been defined as cells containing
cytoplasmic 1A chain but no cytoplasmic light chain and no surface Ig (17, 18).
The information on these cells has primarily involved their phenotypic charac-
terization and localization (19-23), Ig gene rearrangements (24-26), and mito-
genic responses (27-29) . It has also been demonstrated that pre-B cells can
differentiate to antibody-secreting B cells in vitro (30, 31). In one report (32)
IL-1 has been shown to induce the maturation of either pre-B cells from mixed
cell cultures or the pre-B cell lymphoma 70 Z/3 . In addition, it was reported
thata humoral factor from theserum ofNZB mice couldenhance the maturation
ofB lineage precursor cells (33) . Finally, Landreth et al . (34) have demonstrated
the presence of a factor (or factors) that stimulated the formation of pre-B and
B cells in cultures ofhuman or mouse bone marrow .
Although there has been progress in understandingB cell genesis, the major
impediment to the study of lymphocyte development has been the difficulties
associated with obtaining highly enriched populations of viable B cell precursors .
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A long-term bone marrow culture system recently developed (35, 36) has proven
to be a reliable source of highly enriched B cell precursors with which to
characterize the factors required for the growth and maintenance of precursor
B cells . The stromal cells isolated from our long-term cultures, as shown by
others (37, 38), have proven to be the source of soluble factors that can support
the in vitro growth of B precursor cells .
We have extended these observations and used factor-dependent B cell pre-
cursors obtained from long-term cultures as the basis for development of a rapid
and quantitative proliferation assay to detect a soluble growth factor active on
precursor B cells . In addition, we have derived from the stromal elements of a
bone marrow culture, a clonal cell line (designated IxN/A6) that secretes this
growth factor activity in serum-free medium . The development of both a rapid
and specific bioassay as well as a clonal source of the growth factor has allowed
us to use conventional biochemical methods to purify a factor active in the
development ofimmature B cells which we have designated lymphopoetin 1 (LP-
1) .'
Materials and Methods
B Cell Precursor Population .
￿
All cultures were initiated and maintained as described
(36) in RPMI 1640 supplemented with 5% FCS (Irvine Scientific, Santa Clara, CA), 50
AM 2-ME, 50 U/ml penicillin, 50 tag/ml streptomycin, and 2 MM L-glutamine . Our
cultures routinely yielded cells that wereB220+ , surface u , la- , Thy-1 .2- , and Mac-1 - by
cell surface analysis using an EPICS-c FACS . The cells exhibited a lymphocytic appearance
with a large nucleus and a small rim of cytoplasm, which is consistent with a pre-B cell
phenotype .
LP-1 Biological Assay.
￿
The nonadherent cells were removed from the adherent stromal
layers by gentle pipetting, pelleted by centrifugation, and resuspended in 1-2 ml of
Iscove's modified Dulbecco's Medium (IMDM) containing 5% FCS, 50 U/ml penicillin,
50 jug/ml streptomycin, and 2 MM L-glutamine (assay medium).
The cells were then applied to a small column of Sephadex G-10 to remove any
contaminating adherent or stromal cells and were incubated at room temperature for 10
min (39). The precursor B cells were then eluted with assay medium, washed, and
resuspended to 2.5 x 10 5 cells/ml in assay medium . The samples to be assayed were
serially diluted in individual wells of a 96-well microtiter plate (No . 3596 ; Costar,
Cambridge, MA) in a final volume of50 Al . 50 AI of the cell suspension (12,500 cells/well)
was added to each well and the plates were incubated for 48 h in a humidified C02
incubator containing 7 .5% C02 and 5% 0 2 , balance N2 . The cultures were pulsed the
final 4 h of incubation with 2 ACi/well of ['H]TdR 60-80 Ci/mmol, New England
Nuclear, Boston, MA) in a volume of 25 AI . Cultures were harvested with an automated
harvester onto glass fiber filtersand the radioactivity was determined by liquid scintillation
counting . 1 U ofLP-1 is defined as the amount of factor required to induce a half-maximal
[sH]TdR incorporation under the conditions of the LP-1 assay.
Generation of the LP-1-producing Cell Line (IxN/A6) by Transfection.
￿
Adherent bone
marrow stromal cells were transfected with the plasmid pSV3neo containing the trans-
forming sequences ofSV40 (40) using the calcium phosphate procedure (41) as modified
by Wigler et al . (42) . The transfected adherent cells were removed with trypsin/EDTA
and cloned by limiting dilution . The supernatants from the resultant clones were tested
for growth factor activity and the best producer (IxN/A6) was expanded for further
study . This cell line has been monitored monthly for the presence of mycoplasma by both
mycoplasma culture and the Gen-Probe mycoplasma detection kit (San Diego, CA) and
has been consistently found to be negative .
' Abbreviations used in this paper:
￿
G/M-CSF, granulocyte/macrophage colony-stimulating factor;
IMDM, Iscove's modified Dulbecco's medium ; LP-1, lymphopoetin 1 ; RP, reversed-phase .990
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LP-1 Production.
￿
Conditioned medium from IxN/A6 cells was generated in 1,750-cm2
tissue culture roller bottles (No. 3029; Falcon Labware, Oxnard, CA) in the following
manner. When the cells reached confluence the medium was replaced with 1 liter/roller
bottle of serum-free RPMI supplemented with 2.3 gm/liter glucose and 1 .54 gm/liter of
sodium bicarbonate, containing as a stimulant 1 kg/ml LPS Salmonella typhimurium, (No.
3125-25; Difco Laboratories Inc., Detroit, MI). The bottles were gassed with 10% C02
in air and incubated for 6 d. The supernatant was harvested and then concentrated 20-
fold in an Amicon Corp. (DC10; Danvers, MA) hollow fiber apparatus (10,000 mol wt
cutoff). The crude concentrates were sterilized by filtration before assay and purification.
Source ofOtherFactors.
￿
The factors used and the corresponding assay systems include
human rIL-la (43-45), natural and recombinant human IL-10 (43-45), human rIL-2
(46-48), murine IL-3 (48, 49), murine IL-4 (50, 51), murine IL-5 (52), murine granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) (53, 54), human G-CSF (55) and
murine M-CSF (56), murine IFN-a and -,B (Lee Biomolecular, San Diego, CA), and human
transforming growth factor ,B (Calbiochem-Behring Corp., LaJolla, CA).
DEAE-Sephacel Chromatography.
￿
1 liter ofthe crude concentrated conditioned medium
was adjusted to pH 8 with 1 N NaOH and diluted with sterile distilled water to a
conductivity of 1 m Siemen/cm (a conductivity of 1 m Siemen/cm corresponds to a
sodium chloride concentration of 100 mM). The concentrate was then applied to a DEAE-
Sephacel (Pharmacia Fine Chemicals, Piscataway, NJ) column (5.0 X 15 cm) previously
equilibrated with 20 mM Tris-HC1 (pH 8), containing 100 mM NaCl. The effluent was
monitored by OD28o and the protein-containing flow-through fraction was collected for
further purification.
SP-Trisacryl Chromatography.
￿
The nonbinding fraction from the DEAE-Sephacel col-
umn was adjusted to pH 5 with 1 M citric acid (free acid). This was then applied directly
to a column (3.2 X 12.5 cm) of SP-Trisacryl (LKB Instruments, Inc., Gaithersburg, MD)
that had previously been equilibrated in 10 mM citrate (pH 5.0) containing 100 mM
NaCl. The column was washed with five column volumes of equilibration buffer followed
by washing with five column volumes of 20 mM Tris-HCl (pH 8). When the pH of the
column effluent reached pH 8 and the OD28o had returned to baseline values the column
was eluted with a 1 liter linear gradient from 0.0 to 0.5 M sodium chloride in 20 mM
Tris-HCl (pH 8). The elution was carried out at a flow rate of 50 ml/h and 10-ml fractions
were collected and assayed for the presence of LP-1 .
Blue B Chromatography. Pooled LP-1-containing fractions from two separate SP-
Trisacryl elutions were pooled and applied directly to a column (2.5 X 40 cm) of Blue B
agarose (Amicon Corp.) that had previously been equilibrated in 20 mM Tris-HC1(pH 8)
containing 125 mM NaCl. The sample was applied at a flow rate of 15 ml/h. After
washing with equilibration buffer until the OD28o had returned to baseline values, the
column was eluted with a 1 liter linear gradient from 0.125 to 2 M NaCl in 20 mM Tris-
HCl (pH 8). 10-ml fractions were collected at a flow rate of 25 ml/h and assayed for LP-
1 activity.
Reversed-phase HPLC (RP-HPLC). HPLC was performed with a Waters Associates
(Milford, MA) liquid chromatograph equipped with two model 510 pumps, a model 720
system controller, and a model 441 absorbance detector monitoring at 214 nm essentially
as previously described (48). Large sample volumes were pumped onto columns with a
Milton Roy minipump (Laboratory Data Control, Rivera Beach, FL). Solvents were
purchased from Burdick & Jackson Laboratories Inc. (Muskegon, MI).
Fractions containing LP-1 activity from the Sepharose Blue B column were applied at
a flow rate of 5 ml/min to an 8 mm X 10 cm radial PAK cartridge (Waters Associates)
containing 15-20 j,m Vydac C-4 reversed-phase silica (The Separations Group, Hesperia,
CA). Water containing 0.1% trifluoroacetic acid (TFA, solvent A) was flushed through
the columns until the absorbance at 214 nm was down to baseline levels. At this time, a
linear gradient was established that went from 0 to 100% solvent B (acetonitrile containing
0.1% TFA) at a rate of 1 % solvent B/min and a flow rate of 1 ml/min.
Active fractions after a single HPLC phase were pooled, diluted with two volumes of
0.9 M acetic acid and 0.2 M pyridine (pH 4 .0, buffer A2), and were applied to the sameNAMEN ET AL.
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column that had been reequilibrated in the pyridine-acetate solvent system. A gradient
of solvent B2 (0.9 M acetic acid, 0.2 M pyridine, and 60% N-propanol) was established
that went from 0 to 20% solvent B2 in 10 min and from 20% B2 to 84% B2 in 100 min,
at a flow rate of I ml/min.
The fractions containing activity from this second HPLC phase were pooled, diluted
with two volumes of solvent A2, and applied to a 3.9-mm by 30-cm radial PAK column
packed with 10 jAm Vydac C-18 reversed-phase silica that had been previously equilibrated
in 20% solvent B2. A gradient of solvent B2 from 20 to 84% was used to elute protein off
the column. Fractions containingactivity from the third phase of HPLC were diluted with
two volumes of solvent A, (0 .1% TFA) and applied to the C-18 column previously
equilibrated in 20% solvent B, (acetonitrile, 0.1% TFA) and a gradient of solvent B,
established from 20 to 100% B, at a rate of change of 1 % per minute and a flow rate of
1 ml/min was used to elute LP-1 .
Generation ofthe IxNl2b Cell Line.
￿
The nonadherent precursor B cells from an 8-wk-
old bone marrow culture were seeded into 96-well trays at 0.3 cells/well in assay medium
containing 500 U/ml of partially purified LP-1 . After 5 d of incubation, one-half of the
medium was replaced with fresh assay medium containing LP-1 . By the twelfth day after
seeding, growth was visually obvious in 12 of the 96 wells. These clones were expanded
and tested for their dependency upon exogenous LP-1 . One of the clones selected,
designated IxN/2b has been grown in the absence of any exogenous feeder or stromal
cells for >10 mo. This cell line is absolutely dependent upon the presence of exogenous
LP-1 for continued growth and viability.
Radiolabeling of LP-1 and Binding to Intact Cells.
￿
An aliquot (25 'Ul) of the fraction
containingbiological activity from the fourth HPLC column was radiolabeled with `251 by
the enzymobead procedure used for the radiolabeling of other lymphokines (57).
LP-1-dependent cells (IxN/2b) and LP-1 nonresponsive cells (CTLL, a murine IL-2-
dependent T cell line [46]) were washed in RPMI 1640, suspended at a concentration of
2 X 108 cell/ml in RPMI 1640 containing 20 mM Hepes buffer, 0.2% sodium azide, and
2% BSA, pH 7 .2, and an aliquot of radiolabeled LP-1 containing 2.0 X 106 cpm with or
without 5,u1 of the unlabeled LP-I as a cold competitorwas added. Tubes were incubated
for 1 h at 37°C with rocking and then the cells washed three times in cold PBS by
centrifugation. Afterthe finalwash the cell pellet was extracted in 50 wl ofPBS containing
1 % Triton X-100, PMSF (2 mM), pepstatin (10 uM), leupeptin (10 uM), o-phenanthroline
(2 mM), and EGTA (2 mM). The suspension was centrifuged and aliquots of the
supernatant were analyzed by autoradiography of the dried gel after polyacrylamide gel
electrophoresis as previously described (57).
SDS-PAGE.
￿
SDS-PAGE was performed as described by Laemmli (58). Material puri-
fied through four phases of RP-HPLC was evaporated to dryness under vacuum in a
SpeedVac apparatus (Savant Instruments, Inc., and redissolved in a small volume of SDS
sample buffer without 2-ME. The sample was electrophoresed onto a 12% acrylamide
gel, the gel in the appropriate lane was sliced into 1-2-mm sections, and each section was
minced and eluted by diffusion overnight into 0.2% SDS and the biological activity in
each fraction was then determined. The active fractions were pooled and an aliquot was
analyzed after electrophoresis on a Phastgel PAGE System (Pharmacia Fine Chemicals)
using a 10-15% gradient gel. Proteins were visualized using a silver-staining method
recommended by Pharmacia Fine Chemicals.
ProteinAssay.
￿
Protein determinations were carried out using a modified Bradford dye-
bindingassay (Bio-Rad Laboratories, Richmond, CA). BSA was used to establish a standard
curve for each assay performed.
Results
The development of an in vitro culture system for B cell precursors (35, 36)
led to our initial interest in characterizing factors that might regulate their
growth and differentiation. We speculated, based upon the apparent strict growth
dependence of these precursors on their stromal feeder layers that these cells99 2
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produced a B cell precursor growth stimulatory activity. Characterization of this
growth activity was considered feasible if we could both develop a quantitative
assay and identify a good cellular source of the growth-promoting activity.
Derivation of the IxN/A6 Cell Line.
￿
Our initial attempts to develop a bioassay
used cell-free supernatants from stromal bone marrow (feeder) layers as a source
of factors. Generally the assay results were equivocal because a stimulation index
of only two- to fourfold over background was observed (data not shown). This
level of stimulation was consistent with results obtained by others (37, 38).
Initially, it was not clear if the low level of stimulation was due to a paucity of
factor production, the presence of other suppressive or inhibitory materials in
the conditioned medium, or an absolute requirement for direct cell contact. We
considered that an immortalized cell line might circumvent some of these
difficulties and allow us to establish a suitable cellular source of this growth
factor. We therefore established stromal cell lines after the transfection of
primary adherent stromal cells with the plasmid pSV3neo (40), which encodes
the large and small T antigens of SV40 . A number ofimmortal cell lines emerged
from the transfected cultures but not from uninfected control cultures. One of
the resultant clonal cell lines, designated IxN/A6 (Fig. 1 B), was found to produce
a factor capable of supporting the growth of precursor B cells. Presumably, the
immortalization of this cell line was due to the transfection by pSV3neo, as
immunoprecipitation results confirmed that the cells expressed the SV40 large
and small T antigens (data not shown). Both the IxN/A6 cells themselves and
their culture supernatants could stimulate the proliferation of precursor B cells.
Subsequently, it was found that in serum-free medium, stimulation ofthe IxN/A6
cells with 1 wg/ml LPS could increase the levels of factor produced fourfold.
Biological Assay for LP-1.
￿
The cellular basis of the LP-1 assay was a highly
enriched population of precursor B cells obtained from our long-term bone
marrow cultures. These cells exhibited a typical lymphocyte morphology as
shown in Fig. 1 A. We found a further enrichment step, G-10 Sephadex passage,
was necessary to obtain suitable biological assay results.
The results of a typical bioassay response to (A) LPS-stimulated crude IxN/A6
conditioned medium and (B) a 20-fold hollow fiber concentrate are graphically
shown in Fig. 2. In this particular preparation the crude conditioned medium
contained 19 U/ml and the 20X concentrate contained 642 U/ml of LP-1 . The
levels of LP-1 obtained in the large batches of crude conditioned medium ranged
between 10 and 100 U/ml.
The LPS stimulant alone had no effect on the precursor B cells. The 20X
hollow fiber concentration step often resulted in a recovery of >100% activity,
presumably due to removal of inhibitory metabolic cellular products. The stim-
ulation index of the LP-1 assay was routinely in the range of 15-20 times the
level of background thymidine incorporation.
Specificity of the LP-1 Assay.
￿
Before initiating efforts to purify the LP-1 from
the IxN/A6 cells, it was considered important to determine whether other known
factors could stimulate pre-B cell proliferation and to assess the specificity of our
established assay. We therefore evaluated the specificity of this assay system with
other defined factors. None of the factors tested, including IL-la, IL-1,8, IL-2,
IL-3, IL-4, IL-5, GM-CSF, G-CSF, CSF-1, IFN-a, 0, and y, neuroleukin, andNAMEN ET AL.
FIGURE I .
￿
Typical morphology of precursor B cells derived from long-term bone marrow
cultures and the IxN/A6 . Wright-Giemsa-stained preparations of (A) nonadherent precursor
B cells obtained from 8-wk-old bone marrow cultures ; (B) the LP-1-secreting cell line IxN/A6
derived from the stromal elements ofa bone marrow culture . x 400.
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TABLE I
Purification ofLymphopoetin 1 (LP-1)
FIGURE 2. Proliferative response
of long-term bone marrow culture-
derivedprecursor Bcellsin the LP-1
quantitative microassay. (A) The re-
sponse to crudeconditioned medium
from a 6-d stimulation of IxN/A6
cells, and (B) the response to a 20X
concentrate of the same conditioned
medium. The top portion of each
paneldepicts the raw data. Each cpm
value is convertedto a percentage of
the maximum cpm. A logit transfor-
mation (63) is then applied to these
percentages to obtain data that are a
linear function of the 1094 dilution.
Values preceding the maximum of
each dilution set are excluded from
the linear regression analysis.
Weighted linear regression is used to
fit parallel lines to each sample and
standard and units per milliliter can
be computed in terms of the dilution
that gives half-maximal activity.
* The crude concentrated conditioned medium usually contains some level of
toxic/inhibitory materials, presumably dueto metaboliccellular products. Most
of theseinhibitory materials are removedby the DEAE-Sephacel step and the
yields arebasedon theactivity after DEAE-Sephacel chromatography.
Specific activity based on protein values estimated from silver staining.
transforming growth factor a induced stimulation of thymidine incorporation
over background levels throughout a range of factor concentrations (data not
shown). In addition, purified LP-1 did not elicit any response in standard
bioassays for IL-1, IL-2, IL-3, GM-CSF, IL-4, IL-5, G-CSF, CSF-l, and IFN.
However, cell-free supernatants from the IxN/A6 cell line were found to stim-
ulate the formation of murine macrophage-type colonies in soft agar. We subse-
quently determined that fractionation of the conditioned medium by DEAE-
Sephacel chromatography completely resolved the colony-stimulating activity
from the precursor B cell growth-promoting activity.
Purification and Characterization of LP-1.
￿
Table I summarizes the results of
the procedures used to purify LP-1 . At pH 8.0 and 100 mM NaCl, the LP-1
activity in the concentrated medium from IxN/A6 cells did not bind to a DEAE-
Sephacel column, although 90% of the total protein present in the crude
conditioned medium, including that responsible for macrophage colony-stimu-
Step SA
Ulwg
Purification
fold
Yield
1: Concentrate 0.38 1 -*
2: DEAF-Sephacel(flow-through) 4.63 12.2 100
3: SP-Trisacryl 153 403 113
4: Blue B Agarose 423 1113 80
5: RP-HPLC* 8 X 104 2 X 105 50
6: SDS-PAGE 4 X 106 10 X 106 350 0.04
O
0.06
00.04
ao N
0.02
N
E
10 20 30 4,0 50 60 70
Froction Number
30 40 50 60 70 80
Retention Time (min)
-pool-
/iocaon number
￿
0 20 40 60 80 110
z~ a
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FIGURE 3. SP-Trisacryl chromatography
of the nonbinding flow-through material
' 0.2-
￿
after DEAE-Sephacel chromatography. A
linear gradient ranging from 0.0 to 0.5 M
--
￿
NaCl in 10 mM Tris-HCI, pH 8, was used
0.1 o
￿
to elute the LP-1 . The active fractions in
Z
￿
dicated (numbers 29-42) were pooled for
subsequent purification.
FIGURE 4. Chromatography on Blue B aga-
rose. The active fractions from SP-Trisacryl
chromatography were applied directly to the
Blue Bagarose. Asteep gradient rangingfrom
0.0 to 2.0 M NaCl was then used to elute the
LP-1 . Those fractions containing biological ac-
tivity were pooled as indicated for further pu-
rification by RP-HPLC.
FIGURE 5.
￿
First-phase purification of LP-1 by RP-
HPLC. The active fractions from a typical Blue B
chromatography purification were applied to a C4
column and eluted with increasing concentrations of
acetonitrile in 0.1 % TFA.
lating activity, did bind to the column. The chromatographs of subsequent steps,
which included SP-Trisacryl, Blue B agarose, and four separate reversed-phase
HPLC protocols, are shown in Figs. 3-6 and resulted in a 200,000-fold purifi-
cation of LP-1 activity.
The processing of 800 liters of crude conditioned medium in this fashion
resulted in four HPLC column fractions that contained a total of 5 X 106 U of
LP-I activity. Analysis of this material by SDS-PAGE and silver staining or after
iodination, SDS-PAGE, and autoradiography (Fig. 7, lane a) revealed that a
number of proteins were still present at this stage of purification. The major
protein present in this material exhibited a molecular mass of 18 kD and faint
bands above and below this band were detectable.
Two experiments were performed to identify the protein in this mixture that
was responsible for LP-1 activity. In the first, LP-1 was applied to SDS-PAGE
under nonreducing conditions. After the completion of electrophoresis the gel
was cut into 1-mm bands and the protein in each band was eluted into medium
and assayed for biologicalactivity. The results are shown in Table II and indicated
that the biological activity was associated with a protein of Mr 25 X 10' and was996
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FIGURE 6.
￿
Fourth-phase purification of LP-1 by
RP-HPLC . The active fractions after three hases
of RP-HPLC were applied to a C,8 column and
eluted with a linear gradient of increasing concen-
trations of acetonitrile in 0.1%TFA .
0
FIGURE 7 . Binding of ' 25I-LP-1 to LP-1-dependent IxN/2b
cells. (Lane a) Iodinated starting material . IxN/2b (lanes b and
c) andCTLL (lanes dand e) cells (2 x 107) were incubated with
'$5I-LP-1 (2 X 10 6 cpm) both in the presence (lanes cand e) and
absence (lanes b and d) of a 50-fold molar excess of unlabeled
LP-1 for 1 h at 37°C . Cells were then harvested, washed, and
extracted with PBS-1%Triton containing amixture ofprotease
inhibitors as described under Materials and Methods . Aliquots
corresponding to 2 X 106 cells were boiled for 3 min in sample
buffer containing 2% SDS and subjected to electrophoresis on
a 10-20% linear gradient gel .
distinct from the region of the gel corresponding to that containing theM r 18 X
103 protein band . No activity was isolated when electrophoresis was . performed
under reducing conditions .
In the second experiment, '25I-labeled LP-1 (Fig. 7, lane a) was absorbed to
cells that responded to this factor (IxN/2b) . Afterincubation with '25I-LP-1, the
cells were washed and then extracted with PBS containing 1% Triton X-100.
An aliquot of this material was then analyzed by SDS-PAGE and autoradiogra-
phy. The results showed (Fig. 7, lane b) that of the '25I-labeled proteins present
in the radiolabeled preparation, only a protein ofM r 25,000 appeared to
specifically bind to cells that responded to LP-1 . Excess unlabeled LP-1 (Fig . 7,
lane c) inhibited the binding of this protein and cells that do not respond to LP-
1 failed to bind the M r 25 X 10 5 protein (Fig . 7, lane d) . The results of both
experiments suggested that a protein ofM r 25 X 103 was responsible for B cell
precursor growth-promoting activity .
Theretention ofPBGF activity after SDS-PAGE suggested that this procedure
could be used as the final step in the purification of this protein . The results
depicted in Fig. 8 showed that, as found in the pilot experiment, LP-1 activity
b a
x
e0
E
3 w 60 v
E 0 o
3 2 40 p
a
J 20
C v
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TABLE II
Recovery ofLP-1 AfterSDS-PAGE
Discussion
LP-1 that had been purified through four steps of HPLC was dried,
reconstituted in nonreducing sample buffer, and applied to polyacryl-
amide gel as described in the Materials and Methods .
* After electrophoresis, the gelwas sliced into 1-mm pieces and each piece
was eluted and tested for biological activity in the LP-1 assay.
t Slice 1 corresponded to the position of theM, 43,000 marker ; slice 5,
with theM r 31,000 marker; slice 9 with theM, 21,000 marker ; and slice
12, with the M, 14,000 marker .
FIGURE 8 .
￿
Purification of LP-1 by SDS-PAGE . The
active fractions after four phases of RP-HPLC were
evaporated to dryness, redissolved in nonreducing
SDS-PAGE sample buffer, and electrophoresed on a
12% polyacrylamide gel. The gel was sliced, minced,
and the activity was eluted in 0.2% SDS . An aliquot
of each fraction was analyzed by Phastgel-PAGE and
silver staining as recommended by Pharmacia Fine
Chemicals.
eluted at a position coinciding with a protein ofM r 25 x 103 . PAGE analysis of
this bioactive fraction revealed a single protein detected by silver staining. The
final specific activity was estimated to be 4 x 106 U/wg protein, which would
represent a purification of 107-fold from the starting material . The purified LP-
1 was active in the in vitro bioassay at a concentration of 10-"M.
The later stages of B cell development have been well characterized at the
cellular and molecular level. In contrast, very little is known about the events or
factors involved in development ofimmature lymphocytes . Recently, a number
of studies have appeared that use long-term lymphoid bone marrow cultures in
Slice number* Mol wt*
x 10 1
Amount
recovered
U/ml
Recovery
1 43 - -
2 - -
3 - -
4 815 -
5 31 2,912 3.5
6 11,374 13.6
7 40,000 44.0
8 19,011 22.8
9 21 1,951 2.3
10 247 -
11 - -
12 14 - -
Total 86.2998
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the study of B lymphocyte growth and development (59-61). Generally, the
information derived from these studies has been restricted to phenotypic and
morphological description of the culture system and the cells produced in these
cultures. However, recent evidence that soluble factors from stromal cells could
control precursor B cell growth has emerged (37, 38). In addition, it has been
reported that precursor B and precursor T lymphocyte clones respond to IL-3
and IL-4 (62), cytokines previously associated with the proliferation and differ-
entiation of a multipotential stem cell from the bone marrow and with more
mature B and T cells, respectively.
To characterize the factors required for precursor B cell growth we exploited
in vitro culture systems in two ways. First, precursor B cells cultured in vitro
proliferate only when grown in the presence of stromal cells or when supple-
mented with medium conditioned by the growth of these cells. This property
served as the basis for the developmentofa rapid and specific bioassay that could
be used to detect this activity. A panel of purified natural or recombinant
cytokines, including those that have been reported to stimulate various B cell
responses, were tested in the LP-I assay, and all failed to stimulate the prolifer-
ation of precursor B cells. In a similar fashion, the assays used to monitor the
different activities associated with this panel all failed to respond to LP-1,
indicating that the material responsible for the LP-I activity was distinct from
the well-characterized proteins detected by these assays. Secondly, we established
a stable stromal cell line by transforming the primary stromal cell cultures with
a plasmid vector encoding the transforming sequences of SV40. This procedure
resulted in the isolation of a clonal cell line, IxN/A6, that secreted enhanced
levels of LP-I activity.
The purification strategy revealed that LP-I activity was stable to a wide
spectrum ofconditions that included extremes of pH (2.1 to 8.0) and solvents
containing acetoriitrile or n-propanol. Resolution of the activity by PAGE gave
conclusive proof that the LP-1 activity was associated with a protein ofM, 25 x
10' and was stable in the presence ofSDSand heat. In contrast, reduction ofthe
protein by the addition of 2-ME completely destroyed its biological activity.
Preparative SDS-PAGE resulted in the resolution of a single protein ofM,. 25 x
106 that coincided with the biological activity. Moreover, radiolabeled LP-1
bound specifically to cells that respond to this cytokine, suggesting that LP-1,
like other polypeptide hormones, binds to specific receptors on the surface of
cells. The purification protocol resulted in a 107-fold purification with a final
yield of 35%. The purified LP-I exhibited a specific activity of -r4 x 106 U/Ag
protein and was active at a concentration of 10-`6 M.
The availability of this novel factor in pure form will allow us to elucidate its
role within the developmental pathway of lymphogenesis and to define more
precisely the repertoire ofcells that have thecapacity to respond to this cytokine.
Summary
We have used a biological assay system we developed to biochemically purify
a previously uncharacterized murine lymphopoetic growth factor designated
lymphopoetin 1 (LP-1). This factor is capable of stimulating the proliferation
and extended maintenance ofprecursor cells ofthe B lineage. A stromal cell lineNAMEN ET AL.
￿
999
producing LP-1 was established after transfection of primary stromal cultures
with a plasmid encoding the transforming genes ofSV40 . This factor was purified
to a single 25-kD species from the culture supernatant of an adherent stromal
cell line. This material acts on immature lymphocytes, it binds to specific
receptors on cells, and is distinct from previously described hematopoietic factors.
LP-1 has been purified some 107-fold with an overall recovery of 35%. The
purified protein exhibits a specific activity of ^-4 x 106 U/Ag of protein and is
active at a half-maximal concentration of 10-'3 M.
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